Mevastatin | Compactin | HMG-CoA Reductase Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Mevastatin

美伐他汀 /Mevastatin {[allProObj[0].p_purity_real_show]}

货号：A445160 同义名： Compactin;ML236B

Mevastatin is the first discovered statin-class HMG-CoA reductase inhibitor used as a cholesterol-lowering agent isolated from Penicillium citinium.

Mevastatin 化学结构
CAS号：73573-88-3

Mevastatin 3D分子结构
CAS号：73573-88-3

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Mevastatin 纯度/质量文件产品仅供科研

货号：A445160 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

Mevastatin 生物活性

描述

HMG-CoA reductase, the rate-limiting enzyme in the process of cholesterol synthesis in liver cells, catalyzes the production of mevalonate. Inhibiting HMG-CoA reductase inhibits cholesterol synthesis. Mevastatin reversibly inhibits HMG-CoA reductase and competes with HMG-CoA, whose Ki value is about 1 nM^[3]. in vitro, at 0.01 pg/mL (26 nM), it reduced cholesterol synthesis by 50% compared with the control group^[2]. In addition, mevastatin can completely inhibit L cell growth at 1.3 μM. Mevastatin can also influence cell cycle and change cell morphology in cultured fibroblasts^[3]. In vivo, Mevastatin reduced serum cholesterol levels three hours after oral administration at doses of 5 mg/kg and 20 mg/kg. At a dose of 20 mg/kg, it reduces serum cholesterol levels by about 30 percent^[2]. Mevastatin reduces cholesterol production in the liver by competitively inhibiting HMG-CoA reductase. Cholesterol levels were reduced only after 28 days of treatment and were not associated with a reduction in infarcts. After 14 days of high-dose treatment, baseline absolute cerebral blood flow was 30% higher^[1]. In patients with familial hypercholesterolemia, mevastatin is effective in lowering plasma cholesterol. Treatment at 50 mg/day for 2 months reduced total cholesterol in FH heterozygous patients by 25%^[3].

Mevastatin 动物研究

Dose	Rabbit: 0.02 mg/kg^[3] (intra-articular injections) Rat: 5 mg/kg, 20 mg/kg^[2] (p.o.) Mice: 2 mg/kg, 20 mg/kg^[1] (s.c.)
Administration	Intra-articular injections, p.o., s.c.

Mevastatin 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02441400	-		Recruiting	May 2019	Argentina ... 展开 >> Fundacion Favaloro Recruiting Buenos Aires, Argentina Contact: Alejandro Nieponice, MD Principal Investigator: Alejandro Nieponice, MD Austria University Hospital Vienna Recruiting Vienna, Austria Contact: Sebastian Schoppmann, MD Principal Investigator: Sebastian Schoppmann, MD Denmark Aarhus University Hospital Recruiting Aarhus, Denmark Contact: Jan B Pedersen, MD Principal Investigator: Jan B Pedersen, MD Germany SANA Klinikum Lichtenberg Recruiting Berlin, Germany Contact: Dirk Federlein Principal Investigator: Dirk Hartmann, MD Evangelisches Krankenhaus Castrop-Rauxel Recruiting Castrop Rauxel, Germany Contact: Pravin Thattamparambil, MD Principal Investigator: Pravin Thattamparambil, MD St. Marienstift Krankenhaus Friesoythe Recruiting Friesoythe, Germany Contact: Ralf Weise, MD Principal Investigator: Ralf Weise, MD Hospital zum Heiligen Geist Fritzlar Recruiting Fritzlar, Germany Contact: Carsten Bismarck Principal Investigator: Carsten Bismarck, MD Klinikum Garmisch-Partenkirchen Recruiting Garmisch-Partenkirchen, Germany Contact: Holger Vogelsang Principal Investigator: Holger Vogelsang, MD Asklepios Klinik Altona Recruiting Hamburg, Germany Contact: Gero Puhl Principal Investigator: Gero Puhl KRH Klinikum Siloah Hannover Oststadt Recruiting Hannover, Germany Contact: Ahmed Madisch Principal Investigator: Ahmed Madisch, MD Evangelisches Krankenhaus Herne Recruiting Herne, Germany Contact: Matthias Kemen, MD Principal Investigator: Matthias Kemen, MD Klinikum Konstanz Recruiting Konstanz, Germany Contact: Ulrike Petzsche Principal Investigator: Marcus Schuchmann, MD Heilig Geist-Krankenhaus Köln Recruiting Köln, Germany Contact: Ernst Eypasch, MD Principal Investigator: Ernst Eypasch, MD Universitätsklinikum Magdeburg Recruiting Magdeburg, Germany Contact: Frank Benedix Principal Investigator: Ulrike von Arnim Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Mirko Otto Principal Investigator: Kai Nowak, MD Klinikum Memmingen Recruiting Memmingen, Germany Contact: Heinz Schlosser Principal Investigator: Carsten Gutt, MD Friedrich-Ebert-Krankenhaus Neumünster Recruiting Neumünster, Germany Contact: Andrea Pace Principal Investigator: Andrea Pace, MD Asklepios Schwalm-Eder Kliniken GmbH Recruiting Schwalmstadt, Germany Contact: Norbert Hesselbarth Principal Investigator: Felix Meuschke, MD Jung Stilling - Siegen Recruiting Siegen, Germany Contact: Daniela-Patricia Borkenstein Principal Investigator: Joachim Labenz, MD St. Marien-Krankenhaus Siegen Recruiting Siegen, Germany Contact: Dietmar Stephan, MD Principal Investigator: Dietmar Stephan, MD Ev. Krankenhaus Wesel GmbH Recruiting Wesel, Germany Contact: Vivianda Menke Principal Investigator: Vivianda Menke, MD Mexico Hospital San José Recruiting Monterrey, Mexico Contact: David Aguirre Mar, MD Principal Investigator: David Aguirre Mar, MD Netherlands Maastricht University Medical Center Recruiting Maastricht, Netherlands Contact: Nicole Bouvy, MD Principal Investigator: Nicole Bouvy, MD United Kingdom Spire Leicester Hospital Recruiting Leicester, United Kingdom Contact: Chris Sutton Principal Investigator: Chris Sutton, MD University Hospital Southampton Recruiting Southampton, United Kingdom Contact: Abrie Botha Principal Investigator: Abrie Botha, MD 收起 <<
NCT01382511	Pachyonychia Congenita	Not Applicable	Unknown	-	-

Mevastatin 参考文献

[3]The discovery and development of HMG-CoA reductase inhibitors

Mevastatin 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.80mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

Mevastatin 技术信息

CAS号	73573-88-3
分子式	C₂₃H₃₄O₅
分子量	390.513

别名	Compactin;ML236B;Mevastatin, Compactin.;Statin I;NSC 281245;L-637,312;CS 500
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 250 mg/mL(640.18 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02441400	-		Recruiting	May 2019	Argentina ... 展开 >> Fundacion Favaloro Recruiting Buenos Aires, Argentina Contact: Alejandro Nieponice, MD Principal Investigator: Alejandro Nieponice, MD Austria University Hospital Vienna Recruiting Vienna, Austria Contact: Sebastian Schoppmann, MD Principal Investigator: Sebastian Schoppmann, MD Denmark Aarhus University Hospital Recruiting Aarhus, Denmark Contact: Jan B Pedersen, MD Principal Investigator: Jan B Pedersen, MD Germany SANA Klinikum Lichtenberg Recruiting Berlin, Germany Contact: Dirk Federlein Principal Investigator: Dirk Hartmann, MD Evangelisches Krankenhaus Castrop-Rauxel Recruiting Castrop Rauxel, Germany Contact: Pravin Thattamparambil, MD Principal Investigator: Pravin Thattamparambil, MD St. Marienstift Krankenhaus Friesoythe Recruiting Friesoythe, Germany Contact: Ralf Weise, MD Principal Investigator: Ralf Weise, MD Hospital zum Heiligen Geist Fritzlar Recruiting Fritzlar, Germany Contact: Carsten Bismarck Principal Investigator: Carsten Bismarck, MD Klinikum Garmisch-Partenkirchen Recruiting Garmisch-Partenkirchen, Germany Contact: Holger Vogelsang Principal Investigator: Holger Vogelsang, MD Asklepios Klinik Altona Recruiting Hamburg, Germany Contact: Gero Puhl Principal Investigator: Gero Puhl KRH Klinikum Siloah Hannover Oststadt Recruiting Hannover, Germany Contact: Ahmed Madisch Principal Investigator: Ahmed Madisch, MD Evangelisches Krankenhaus Herne Recruiting Herne, Germany Contact: Matthias Kemen, MD Principal Investigator: Matthias Kemen, MD Klinikum Konstanz Recruiting Konstanz, Germany Contact: Ulrike Petzsche Principal Investigator: Marcus Schuchmann, MD Heilig Geist-Krankenhaus Köln Recruiting Köln, Germany Contact: Ernst Eypasch, MD Principal Investigator: Ernst Eypasch, MD Universitätsklinikum Magdeburg Recruiting Magdeburg, Germany Contact: Frank Benedix Principal Investigator: Ulrike von Arnim Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Mirko Otto Principal Investigator: Kai Nowak, MD Klinikum Memmingen Recruiting Memmingen, Germany Contact: Heinz Schlosser Principal Investigator: Carsten Gutt, MD Friedrich-Ebert-Krankenhaus Neumünster Recruiting Neumünster, Germany Contact: Andrea Pace Principal Investigator: Andrea Pace, MD Asklepios Schwalm-Eder Kliniken GmbH Recruiting Schwalmstadt, Germany Contact: Norbert Hesselbarth Principal Investigator: Felix Meuschke, MD Jung Stilling - Siegen Recruiting Siegen, Germany Contact: Daniela-Patricia Borkenstein Principal Investigator: Joachim Labenz, MD St. Marien-Krankenhaus Siegen Recruiting Siegen, Germany Contact: Dietmar Stephan, MD Principal Investigator: Dietmar Stephan, MD Ev. Krankenhaus Wesel GmbH Recruiting Wesel, Germany Contact: Vivianda Menke Principal Investigator: Vivianda Menke, MD Mexico Hospital San José Recruiting Monterrey, Mexico Contact: David Aguirre Mar, MD Principal Investigator: David Aguirre Mar, MD Netherlands Maastricht University Medical Center Recruiting Maastricht, Netherlands Contact: Nicole Bouvy, MD Principal Investigator: Nicole Bouvy, MD United Kingdom Spire Leicester Hospital Recruiting Leicester, United Kingdom Contact: Chris Sutton Principal Investigator: Chris Sutton, MD University Hospital Southampton Recruiting Southampton, United Kingdom Contact: Abrie Botha Principal Investigator: Abrie Botha, MD 收起 <<
NCT01382511	Pachyonychia Congenita	Not Applicable	Unknown	-	-

美伐他汀 /Mevastatin {[allProObj[0].p_purity_real_show]}

Mevastatin 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Mevastatin 质控信息

Mevastatin 生物活性

Mevastatin 动物研究

Mevastatin 临床研究

Mevastatin 参考文献

Mevastatin 实验方案

Mevastatin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

美伐他汀 /Mevastatin {[allProObj[0].p_purity_real_show]}

Mevastatin 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Mevastatin 质控信息

Mevastatin 生物活性

Mevastatin 动物研究

Mevastatin 临床研究

Mevastatin 参考文献

Mevastatin 实验方案

Mevastatin 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Mevastatin 纯度/质量文件产品仅供科研